JNJ4796 是具有口服活性的流感病毒融合性抑制剂，通过抑制血球凝集素 (HA) 介导的融合来中和甲型流感病毒。JNJ4796 和广泛中和抗体 (bnAbs) 的功能类似。

JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs).

Solid

EC50: 12 nM (H1/Bris), 66 nM (H1/Cal), 38 nM (H1/NCa), 22 nM (H1/PR8), 13 nM (H1/SI06), 449 nM (H5/H97), 3.24 μM (H5/Viet).
Hemagglutinin.

Like bnAb CR6261, the mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA that triggers fusion of the viral and endosomal membranes and release of the viral genome into the host cell. has not independently confirmed the accuracy of these methods. They are for reference only.

Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD 50 ) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved.
Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD 90 ), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. van Dongen MJP, et al. A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science. 2019 Mar 8;363(6431).

In Vitro: DMSO : 100 mg/mL (186.02 mM; Need ultrasonic)配制储备液